Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

Hodgkin Lymphoma Clinical Trial

— RATiFY  

Official title:

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma (RATiFY)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05627115
• Other study ID #: UCL 143242
• Secondary ID: 2022-003677-37
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 1, 2024
• Est. completion date: October 1, 2028

Study information

• Verified date: November 2023
• Source: University College, London
• Contact: RATiFY Trial Coordinator
• Phone: +44 (0)2076799860
• Email: ctc.ratify[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to test the effect of tislelizumab treatment in patients with Hodgkin lymphoma. The main question it aims to answer is whether including a drug called tislelizumab in first-line treatment of Hodgkin lymphoma for patients age 60 years and older is effective and well-tolerated. Participants will initially receive tislelizumab infusion every 21 days for 3 doses. After this a PET scan will be performed to assess the response. The subsequent treatment patients receive will depend on the following factors: 1. The lymphoma stage (early stage or advanced stage) 2. The presence or absence of specific high-risk features at the time of diagnosis 3. How well the lymphoma responds to the initial 3 doses of tislelizumab

Description:

Trial patients who are deemed eligible for the trial will receive 3 cycles of tislelizumab which will be administered at a dose of 200 mg (IV) on day 1 of each 21-day cycle. Patients will then undergo a PET-CT scan (PET1). Subsequent treatment is determined by the patient's stage and response to tislelizumab (as determined by PET1). Patients with early stage lymphoma and no high-risk features who respond very well to the initial 3 doses of tislelizumab will receive a further 2 doses of tislelizumab, followed by radiotherapy, followed by tislelizumab once every 21 days for up to 2 years. All other patients will receive a combination of tislelizumab with chemotherapy for between 2 and 6 cycles. Each cycle will last 28 days. Tislelizumab will be given on day 1 and chemotherapy (doxorubicin (also known as Adriamycin), vinblastine and dacarbazine, or AVD) will be given on days 1 and 15, as injections or infusions into a vein. Following this some patients may require radiotherapy depending on their response to treatment. Patients who are in complete metabolic response (CMR) at PET1 will receive 2 fewer cycles of tislelizumab and AVD therapy than those not in CMR. A further 1 or 2 PET scans will be performed to assess how well the lymphoma has responded to the trial treatment, depending on the results of previous scans. After completing the treatment patients will then be followed-up for at least 2 years from the start of their participation in the trial. Note: Initial patients will be recruited to a safety run in. Once 6 evaluable patients have completed 2 cycles of tislelizumab and AVD after PET1 the independent data monitoring committee (IDMC) will review the data, and if considered tolerable, recruitment will continue to the full sample size (80 patients).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: October 1, 2028
• Est. primary completion date: October 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

1. Newly diagnosed untreated classic Hodgkin lymphoma (Stage I-IV)

2. Age 60 years or over

3. In the view of the investigator, fit for combination chemotherapy (includes those who would require planned dose reduction although no lower than 50% doxorubicin)

4. Written informed consent

5. Measurable disease on contrast enhanced CT as defined by Cheson et al., 2014 1 (Nodal lesion of longest diameter 1.5 cm or extranodal lesion of longest diameter 1.0 cm).

6. ECOG performance status 0-2

7. Adequate bone marrow function (Platelets = 75 x 109/L without platelet transfusion for 72 hours, Neutrophils = 1.0 x 109/L without G-CSF for 7 days)

8. Adequate liver function tests (ALT / AST = 2.5 x ULN, total serum bilirubin = 1.5 x ULN)

9. Creatinine Clearance = 30 ml/min as defined by the Cockroft-Gault equation

10. Adequate cardiac function as determined by a transthoracic echocardiogram demonstrating left ventricular ejection fraction is = 50% and confirming the absence of severe valvular heart disease

11. Willing to comply with the contraceptive requirements of the trial

12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures

Exclusion Criteria:

1. Nodular lymphocyte predominant Hodgkin lymphoma

2. History of autoimmune disorders (with the exception of hypothyroidism, type 1 diabetes, vitiligo, alopecia)

3. History of solid organ transplant

4. Grade 2 or higher peripheral neuropathy

5. Presentation with disease causing symptomatic compression of vital structures (e.g. stridor due to tracheal compression). Other cases of radiological compression of vital structures require discussion with TMG prior to registration

6. Women who are pregnant or breastfeeding

7. Active hepatitis B or C infection defined by

1. Hepatitis B surface antigen positivity OR

2. Anti-hepatitis B core antibody positivity with detectable circulating HBV DNA (hepatitis B core antibody patients with undetectable circulating HBV DNA are eligible but must take suitable prophylaxis for reactivation)

3. Anti-Hepatitis C antibody positivity unless patient has been treated for hepatitis C and has undetectable HCV RNA

8. Known HIV infection

9. Positive PCR for SAR-CoV-2 RNA within the 2 weeks prior to registration. Patients with a history of SARS-CoV-2 are required to have a documented negative PCR swab since documented SARS-CoV-2 infection

10. Immunosuppressive therapy within the 2 months prior to registration apart from inhaled, intranasal or topical corticosteroids. Systemic corticosteroids are permitted prior to study entry but must be weaned to 10 mg prednisolone / day for a minimum of 7 days prior to cycle 1 day 1

11. Live vaccine given within 30 days prior to registration

12. Active infection requiring systemic therapy with ongoing symptoms at registration or where the planned duration of therapy would continue beyond cycle 1 day 1

13. Major surgery within 4 weeks prior to registration (excisional biopsy is not considered major surgery)

14. Myocardial infarction, unstable angina, coronary artery bypass graft, cerebrovascular accident or transient ischaemic attack within 6 months prior to registration

15. Previously treated haematological malignancy

16. Solid-organ malignancy active within the last 3 years, except where the natural history or treatment does not have the potential to interfere with assessment of

safety or efficacy of trial treatment, for example:

1. Adequately treated non-melanoma skin cancer considered to be in remission

2. Melanoma in situ following resection

3. Carcinoma in situ of the breast or cervix

4. Carcinoma of the prostate of Gleason grade 6 or less with stable prostate-specific antigen levels

5. Cancer considered cured by surgical resection or unlikely to impact survival in the next 3 years, for example local transitional carcinoma of the bladder or benign tumours of the adrenal gland or pancreas

17. A history of other malignancies should be discussed with the trial management group prior to registration

18. Patient not fit for AVD chemotherapy in the opinion of the investigator

Related Conditions & MeSH terms

• Hodgkin Disease
• Hodgkin Lymphoma
• Lymphoma

Intervention

Drug:
• Tislelizumab, AVD, Radiotherapy
GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy. GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy. GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy. GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy. GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University College, London	BeiGene

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Two-year event-free survival (EFS)	To determine the effect of tislelizumab on 2 year EFS using a response-adapted approach to treatment in the front-line treatment of older patients with Hodgkin lymphoma	2 years after start of treatment
Secondary	The number / percentage of patients with the worst grade of each adverse event	To assess the safety and tolerability of tislelizumab alone and in combination with AVD. Worst grades will be calculated and presented as the number/percentage of patients with each event.	From signing of informed consent until 30 calendar days post last IMP or post last investigational treatment administration (or after this date if the site investigator feels the event is related to an IMP and/or investigational treatment)
Secondary	PET-defined response rates	To determine the effect of single agent tislelizumab on response (overall response rate (ORR), partial response (PR), complete response (CR) and Indeterminate Response (IR)) after 3 cycles of tislelizumab (PET1) and at end of initial treatment (PET2)	After 3 cycles of tislelizumab (PET1) and at the end of the initial treatment (PET2) - up to 2 years after start of treatment
Secondary	Overall survival (OS) of the whole population	To determine the effect of response adapted treatment with tislelizumab on OS	From the date of registration until the date of death (any cause) or the date last seen (patients alive at time of analysis).
Secondary	Progression free survival (PFS) of the whole population	To determine the effect of response adapted treatment with tislelizumab on PFS	2 years after start of treatment
Secondary	EFS in early versus late stage patients	To determine the effect of response adapted treatment with tislelizumab on EFS within early and late stage subgroups of patients	Up to 2 years after start of treatment
Secondary	EFS in interim PET negative and positive patients	To determine the effect of response adapted treatment with tislelizumab on EFS in PET1 negative and positive patients	Up to 2 years after start of treatment
Secondary	Quality of life (QoL) assessed using EQ-5D-5L and FACT-Lym	To assess the effect of treatment on QoL using using EQ-5D-5L and FACT-Lym at baseline and at multiple points during treatment and follow-up. These will be analysed using repeated measures including patient group.	From baseline until 2 years after start of treatment
Secondary	Time to treatment failure	To assess the rate of unplanned Hodgkin lymphoma therapy using Kaplan-Meier survival analysis, with plots and rates at 2 years presented.	From the date of registration until the first date of progression, death or unplanned Hodgkin lymphoma therapy (switch to other regimens or any unplanned consolidation treatment) up to 2 years after start of trial treatment.
Secondary	PFS in early versus late stage patients	To determine the effect of response adapted treatment with tislelizumab on PFS within early and late stage subgroups of patients	2 years after start of treatment
Secondary	OS in early versus late stage patients	To determine the effect of response adapted treatment with tislelizumab on OS within early and late stage subgroups of patients	Up to 2 years after start of treatment
Secondary	PFS in interim PET negative and positive patients	To determine the effect of response adapted treatment with tislelizumab on PFS in PET1 negative and positive patients	Up to 2 years after start of treatment
Secondary	OS in interim PET negative and positive patients	To determine the effect of response adapted treatment with tislelizumab on OS in PET1 negative and positive patients	Up to 2 years after start of treatment
Secondary	Frailty assessed using the Clinical Frailty Score (CFS)	To assess the effect of treatment on frailty using the Clinical Frailty Score at baseline and at multiple points during treatment and follow-up. These will be analysed using repeated measures including patient group.	From baseline until up to 2 years after start of treatment

External Links

•   CR UK & UCL Cancer Trials Centre